youtube
#Ozempic #Wegovy #obesity #diabetes #weightloss #healthcare #pharmaceuticals #novonordisk #drugs #leadership #CEO
Novo Nordisk’s blockbuster diabetes and obesity drugs, Ozempic and Wegovy, are revolutionizing the weight loss industry. Both contain the key ingredient, semaglutide - generating billions in sales. In some cases, patients might need to take the drugs indefinitely to avoid regaining much of the weight they lost. Speaking on Bloomberg’s Leaders With Lacqua, Novo Nordisk CEO Lars Fruergaard Jørgensen gives his personal views on the prospects of lifelong treatment and why the company will need to build a portfolio of interventions.
Watch the full interview:
#bloomberg #leaderswithlacqua #francinelacqua
--------
More on Bloomberg Television and Markets
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance:
Visit for business news & analysis, up-to-the-minute market data, features, profiles and more.
Connect with Bloomberg Television on:
X:
Facebook:
Instagram:
Connect with Bloomberg Business on:
X:
Facebook:
Instagram:
TikTok:
Reddit:
LinkedIn:
More from Bloomberg:
Bloomberg Radio:
Bloomberg Surveillance:
Bloomberg Politics:
Bloomberg Originals:
Watch more on YouTube:
Bloomberg Technology:
Bloomberg Originals:
Bloomberg Quicktake:
Bloomberg Espanol:
Bloomberg Podcasts:
|
2024/06/08
youtube
